3-O-sulfogalactosylceramide (Sulfatide) (SM4)

Sulfatide, chemically known as 3-O-sulfogalactosylceramide, is a major sulfoglycosphingolipid essential for the nervous system, where it constitutes approximately 4% of the total myelin lipids. It is synthesized in the Golgi apparatus of oligodendrocytes and Schwann cells and plays a pivotal role in maintaining the structural integrity of the myelin sheath and the organization of the nodes of Ranvier. Beyond its structural role, sulfatide is involved in diverse biological processes including cell-cell adhesion, signal transduction, and the regulation of blood coagulation through interactions with P-selectin and antithrombin III (PMID: 22403618, 25130385). In clinical pathology, sulfatide is most notably associated with Metachromatic Leukodystrophy (MLD), a lysosomal storage disorder caused by a deficiency in the enzyme arylsulfatase A, leading to toxic sulfatide accumulation and progressive neurodegeneration. Conversely, a significant loss of sulfatide is observed in the very early stages of Alzheimer's disease, suggesting its potential as a diagnostic biomarker. In the immune system, sulfatide acts as a potent antigen presented by CD1d molecules to Type II Natural Killer T (NKT) cells, influencing autoimmune conditions like Multiple Sclerosis and Type 1 Diabetes. Current therapeutic interventions focus on gene therapies and enzyme replacement therapies to manage sulfatide levels in metabolic disorders, while research continues into its role as an immune target (PMID: 21637194, 30655463).

Other names

SulfatideGalactosylceramide-3-O-sulfateSulfogalactosylceramide3'-sulfo-galactosylceramideSM4s

Enzymatic degradation of accumulated substrate; immune modulation via CD1d-restricted natural killer T cell activation; antibody-mediated depletion of reactive immune cells.